Gastroenterology Research and Practice / 2009 / Article / Tab 1

Clinical Study

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Table 1

Patient characteristics at baseline.

Patient IDGender/Age (years)/DiagnosisBody mass index ( )Small bowel (cm)Colon-in-cont. (%)Time since last surgery (years)Wet weight intake (kg/d)Fecal wet weight excretion (kg/d)Parenteral fluid (L/d)Diet energy intake (MJ/d)Fecal energy excretion (MJ/d)Patenteral energy (MJ/d)Duration of HPN (years)Time on GLP-2 (days of )

OBM/49/CD25.5150011. Abd. Pain
JPM/24/CD20.41301002. Abd. Pain
EFPF/55/CD17.55000. unrel. Feedback
JEM/44/UC compl.27.220001.65.93.9no13.85.5nono
JHJM/55/UC compl.22.220002.
UDJF/50/UC compl25.815000.

M male, F female, CD Crohns disease, UC compl. Ulcerative colitis complications, Abd. Pain Abdominal pain, Unrel. Feedback Unreliable feedback.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.